newsfilter
← Latest News
Business Wire·

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of